ARRAY-CGH ANALYSIS ON PHASE III STUDY AGO-OVAR12 WITH BIBF1120 ……

bulanni

题名	ARRAY-CGH ANALYSIS ON PHASE III STUDY AGO-OVAR12 ……
链接	http://apps.webofknowledge.com/full_record.do?product=WOS&search_mode=GeneralSearch&qid=7&SID=1DXTnSeoJTVTBhtLjUk&page=4&doc=35

这是一篇会议摘要，给出的是web of science 上的链接，详细信息如下：
[1]        Pissaloux, D. et al. (2015). ARRAY-CGH ANALYSIS ON PHASE III STUDY AGO-OVAR12 WITH BIBF1120 (NINTEDANIB) IN FIRST LINE TREATMENT FOR ADVANCED EPITHELIAL OVARIAN CANCER (AEOC): A GINECO SUBGROUP ANALYSIS. International Journal Of Gynecological Cancer 25, 518-518.

请有权限的同学在embase数据库检索出来后，如果有的话把摘要复制粘贴过来就可以了，万分感谢！

DrKing

Abstract
BIBF1120 is an oral, multikinase inhibitor. AGO-OVAR12 study reported benefit for PFS in AEOC (ESGO 2013). An ancillary study was delineated to correlate clinical results with genomic alterations from a subset of tumor samples from France and Germany. Array-CGH (aCGH) allowed evaluating copy number alterations (CNA) on BIBF1120 targets and other gene amplifications or homozygous deletions. From the 1366 patients initially enrolled, 150 samples were obtained for analysis. This cohort included 105 high grade serous carcinomas (HGSC), analyses focused on them. Genomic profiles were complex, reflecting a high genomic instability. Recurrent gene amplifications could be observed for CCNE1 (8%), MYC (5.2%), MECOM (3%) and KRAS (3.7%). Recurrent homozygous gene deletions were found for RB1 (2.2%), BRAC2 (1.5%) and PTEN (1.5%). Median PFS (25 months) in the BIBF1120 arm is similar to control arm (NS). The comparison between platinum sensitive group (S) (n=96) versus platinum resistant group (R), (n=9) reported a high prevalence of chromosomes 10 and 11p deletion in S group (69.7%), whereas no deletions were observed in R group. Copy number analysis failed to identify significant differences regarding clinical results. The total number of CNA assessed by the Genomic Index (GI) calculation proved to be an independent factor for prognosis (good for CNA with a GI<100, and worse for highlevel CNA with a GI≥100, p=0.045). The genomic profiles of this subset of patients proved to be representative of HGSC. No biomarkers were found to be correlated with endpoints. Data confirm the GI is an independent prognostic factor for HGSC.